Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208) Dec 6, 2016
DelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting Nov 22, 2016
Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies Nov 18, 2016
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update Nov 15, 2016
RedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 for H. pylori Infection Ahead of Confirmatory Phase III Study Nov 11, 2016
DelMar Pharmaceuticals Presents New VAL-083 Data at Two International Scientific Conferences Nov 8, 2016
RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA® and Expected Timing of Top-Line Results Nov 4, 2016
DelMar Pharmaceuticals Presents Overview of VAL-083’s Unique Anticancer Mechanism at the European Association of Neuro-Oncology (EANO) Annual Meeting Oct 18, 2016
Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease Oct 5, 2016
Resverlogix Announces Filing of Quarterly Financial Statements and Management’s Discussion & Analysis Sep 15, 2016
